Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.69M$2.69Mderived−43.9% vs Q4 2022 Net Income-$5.99M-$5.99MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$733,246−51.4% Operating Incomederived-$3,286,857N/M Operating Cash Flowderived-$1,685,498N/M Free Cash Flowderived-$1,686,998N/M Margins · derivedGross margin27.3%−4.2 pt vs Q4 2022
Operating margin-122.3%−22.7 pt vs Q4 2022
Net margin-223.0%−122.9 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 29, 2024 · 89 d after period end